Stem Cell Transplantation as a Treatment for Multiple Sclerosis

Multiple sclerosis is a neurological autoimmune disease in which a patient’s immune system targets the protective coating around the nerves, known as the myelin sheath. This is a progressive disease, with patients reporting increasing symptoms over time. Developing effective treatments to halt or reverse some of the damage is a major research goal. In a recent paper titled “Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials,” scientists conducted a review of the literature on the benefits of stem cell transplants for this purpose. 

This study combined the data from nine randomized control trials that were looking at the benefits of stem cell therapy (SCT) for treating multiple sclerosis. Their analysis found that there are short term benefits to SCT. Patients who received the treatment noted improved disability scores and reduced brain lesions after two months. However, the data for six and twelve months did not show significant differences from the control groups. Patients who received the SCT reported only minor side effects such as injection site reactions. 

In general, this data suggests that there may be at least a short-term benefit of SCT for patients with multiple sclerosis. However, more data is needed to determine if these benefits are maintained and if other interventions are needed to provide patients with the best possible improvement.

Citation:

Nawar, A.A., Farid, A.M., Wally, R. et al. Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. Sci Rep 14, 12545 (2024). https://doi.org/10.1038/s41598-024-62726-4